Janus Henderson Group PLC bought a new stake in Insmed, Inc. (NASDAQ:INSM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,648,703 shares of the biopharmaceutical company’s stock, valued at approximately $28,292,000. Janus Henderson Group PLC owned approximately 2.64% of Insmed as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Legal & General Group Plc raised its position in shares of Insmed by 2.0% in the 2nd quarter. Legal & General Group Plc now owns 20,173 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 390 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in shares of Insmed by 11.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 16,035 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 1,618 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Insmed by 0.9% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock valued at $3,664,000 after purchasing an additional 1,857 shares in the last quarter. Voya Investment Management LLC raised its position in shares of Insmed by 9.3% in the 2nd quarter. Voya Investment Management LLC now owns 27,960 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 2,389 shares in the last quarter. Finally, American International Group Inc. raised its position in shares of Insmed by 7.1% in the 1st quarter. American International Group Inc. now owns 38,127 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 2,517 shares in the last quarter. 73.08% of the stock is currently owned by institutional investors.

Insmed, Inc. (INSM) opened at 28.01 on Wednesday. Insmed, Inc. has a 1-year low of $10.21 and a 1-year high of $31.84. The stock has a 50 day moving average price of $26.94 and a 200 day moving average price of $18.93. The company’s market cap is $1.75 billion.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.09). Equities analysts forecast that Insmed, Inc. will post ($2.70) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Janus Henderson Group PLC Invests $28.29 Million in Insmed, Inc. (INSM)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/janus-henderson-group-plc-invests-28-29-million-in-insmed-inc-insm/1638513.html.

Several equities research analysts recently issued reports on the company. BidaskClub lowered Insmed from a “sell” rating to a “strong sell” rating in a research report on Monday, August 14th. HC Wainwright reissued a “buy” rating on shares of Insmed in a research report on Wednesday, August 2nd. Evercore ISI assumed coverage on Insmed in a research report on Wednesday, August 16th. They set an “outperform” rating and a $28.00 price target on the stock. ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Finally, Robert W. Baird reissued a “positive” rating and set a $32.00 price target (up from $23.00) on shares of Insmed in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. Insmed presently has a consensus rating of “Buy” and a consensus target price of $34.50.

In other news, Director Melvin Md Sharoky sold 50,000 shares of Insmed stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $27.37, for a total value of $1,368,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald J. Hayden, Jr. sold 45,000 shares of Insmed stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $29.67, for a total value of $1,335,150.00. Following the completion of the sale, the director now directly owns 71,131 shares of the company’s stock, valued at $2,110,456.77. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.